ProfileGDS5678 / 1423198_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 87% 88% 88% 87% 88% 87% 87% 88% 87% 87% 86% 87% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.7711788
GSM967853U87-EV human glioblastoma xenograft - Control 26.7654987
GSM967854U87-EV human glioblastoma xenograft - Control 36.859388
GSM967855U87-EV human glioblastoma xenograft - Control 47.0059288
GSM967856U87-EV human glioblastoma xenograft - Control 56.8147187
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.6299188
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4442387
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.6066287
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8991588
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6645887
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.5837687
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.5682586
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.6882187
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5243986